Rinaldi-Carmona Murielle, Barth Francis, Congy Christian, Martinez Serge, Oustric Didier, Pério Alain, Poncelet Martine, Maruani Jeanne, Arnone Michèle, Finance Olivier, Soubrié Philippe, Le Fur Gérard
Sanofi-Synthelabo Recherche, 371 Rue du Professeur J Blayac, 34184 Montpellier cedex, France.
J Pharmacol Exp Ther. 2004 Sep;310(3):905-14. doi: 10.1124/jpet.104.067884. Epub 2004 May 6.
Based on binding, functional, and pharmacological data, this study introduces SR147778 [5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide] as a highly potent, selective, and orally active antagonist for the CB1 receptor. This compound displays nanomolar affinity (Ki = 0.56 and 3.5 nM) for both the rat brain and human CB1 recombinant receptors, respectively. It has low affinity (Ki = 400 nM) for both the rat spleen and human CB2 receptors. Furthermore, it shows no affinity for any of the over 100 targets investigated (IC50 > 1 microM). In vitro, SR147778 antagonizes the inhibitory effects of CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol] on both the mouse vas deferens contractions (pA2 value = 8.1) and on forskolin-stimulated adenylyl cyclase activity in the U373 MG cell lines (pA2 value = 8.2) but not in Chinese hamster ovary (CHO) cells permanently expressing the human peripheral cannabinoid receptor (hCB2). SR147778 is able to block the mitogen-activated protein kinase activity induced by CP 55,940 in the CHO cell line expressing human brain cannabinoid receptor (IC50 = 9.6 nM) but was inactive in cells expressing hCB2. After oral administration, SR147778 displaced the ex vivo [3H]-CP 55,940 binding to mouse brain membranes (ED50 = 3.8 mg/kg) with a long duration of action, whereas it did not interact with the CB2 receptor expressed in the mouse spleen. Using different routes of administration, SR147778 (0.3-3 mg/kg) is shown to antagonize pharmacological effects (hypothermia, analgesia, and gastrointestinal transit) induced by R-(+)-(2,3-dihydro-5-methyl-3-[[4-morpholinyl]methyl] pyrol [1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone in mice. Finally, per se, SR147778 (0.3-10 mg/kg) is able to reduce ethanol or sucrose consumption in mice and rats and food intake in fasted and nondeprived rats.
基于结合、功能和药理学数据,本研究引入了SR147778 [5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基-N-(1-哌啶基)-1H-吡唑-3-甲酰胺],它是一种对CB1受体具有高效能、高选择性且口服活性的拮抗剂。该化合物对大鼠脑和人CB1重组受体分别表现出纳摩尔亲和力(Ki = 0.56和3.5 nM)。它对大鼠脾脏和人CB2受体的亲和力较低(Ki = 400 nM)。此外,它对所研究的100多个靶点中的任何一个都没有亲和力(IC50 > 1 μM)。在体外,SR147778拮抗CP 55,940 [(1R,3R,4R)-3-[2-羟基-4-(1,1-二甲基庚基)苯基]-4-(3-羟丙基)环己醇]对小鼠输精管收缩(pA2值 = 8.1)以及对U373 MG细胞系中福斯高林刺激的腺苷酸环化酶活性(pA2值 = 8.2)的抑制作用,但对永久表达人外周大麻素受体(hCB2)的中国仓鼠卵巢(CHO)细胞无此作用。SR147778能够阻断在表达人脑大麻素受体的CHO细胞系中由CP 55,940诱导的丝裂原活化蛋白激酶活性(IC50 = 9.6 nM),但在表达hCB2的细胞中无活性。口服给药后,SR147778能取代[3H]-CP 55,940在体内与小鼠脑膜的结合(ED50 = 3.8 mg/kg),且作用持续时间长,而它不与小鼠脾脏中表达的CB2受体相互作用。采用不同给药途径时,SR147778(0.3 - 3 mg/kg)可拮抗R-(+)-(2,3-二氢-5-甲基-3-[[4-吗啉基]甲基]吡咯并[1,2,3-de]-1,4-苯并恶嗪-6-基)(1-萘基)甲酮在小鼠中诱导的药理作用(体温过低、镇痛和胃肠蠕动)。最后,就其本身而言,SR147778(0.3 - 10 mg/kg)能够减少小鼠和大鼠的乙醇或蔗糖消耗以及禁食和未禁食大鼠的食物摄入量。